Skip to main content
. 2023 May 31;14:1188555. doi: 10.3389/fimmu.2023.1188555

Figure 2.

Figure 2

Activation by FPR ligands induces IL-1α as well as MIP-3α and CXCL10 release from keratinocytes. IL-1α release of differentiated N/TERT-1 keratinocytes stimulated for 17 h with either P2C (A), fMLF +/- tBOC (B), MMK1 +/- WRW4 (C), or PSMα3 +/- WRW4 (D) and control (DMSO). Relative amount of released IL-1α by keratinocytes treated with FPR inhibitors as compared to indicated FPR ligands alone (E). MIP-3α release of differentiated N/TERT-1 keratinocytes stimulated for 17 or 36 h with either P2C, fMLF or PSMα3 (F). MIP-3α release after 36 h stimulation with different concentrations of PSMα3 +/- WRW4 (G) or fMLF +/- tBOC (H) and control (DMSO). CXCL10 release of differentiated N/TERT-1 keratinocytes stimulated for 17 or 36 h with either P2C, fMLF or PSMα3 (I). CXCL10 release after 36 h stimulation with different concentrations of PSMα3 +/- WRW4 (J) or fMLF +/- tBOC (K) and control (DMSO). Data in A-K represent means ± SEMs from at least four independent experiments. Data in (A–H) represent cytokine release minus cytokine release by medium-stimulated cells. Ns, not significant, *P < 0.05; **P < 0.01; ***P < 0.001, significant difference versus the indicated FPR ligands as calculated by ordinary one-way ANOVA of baseline corrected data (E) or one-way ANOVA with Dunnett’s multiple comparisons test (G, H, J, K).